Platinum-resistant Ovarian Cancer Clinical Trial
Official title:
A Randomized Phase 2 Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | April 2026 |
Est. primary completion date | April 2026 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subjects must have histologically- or cytologically-diagnosed epithelial high-grade serous cancer of the ovary, fallopian tube cancer or primary peritoneum cancer that is refractory to prior therapy and must have platinum-resistant disease defined as: - Subjects who have received only 1 platinum-based chemotherapy regimen for at least 4 cycles of platinum must have disease progression on treatment or occurring = 26 weeks after their last dose of platinum. - Patients who have progressed following a second course of a platinum based regimen. - Subjects may have up to 2 additional systemic regimens for advanced or metastatic disease. Maintenance regimens (e.g., with a PARP inhibitor or bevacizumab) are not considered separate regimens. - Age greater than or equal to 18 years at the time of signing the informed consent form (ICF). - Has measurable disease per RECIST 1.1. - Has provided written informed consent. - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. - Adequate liver, renal, hematologic, pulmonary and coagulation function. Exclusion Criteria: - Cytotoxic chemotherapy, biologic agent, investigational agent, or radiation therapy within 3 weeks prior to the first dose of CBX-12. - Subjects who are currently receiving any other anticancer or investigational agent(s). - Clinically significant intercurrent disease. - Active human immunodeficiency virus (HIV) infection. - Active hepatitis B or C infection. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Cybrexa Therapeutics |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Subjects With Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)] | ORR is defined as the proportion of subjects achieving a confirmed best overall response (BOR) of CR or PR defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. | Randomization to progressive disease (PD) (Up to approximately 21 months) | |
Secondary | Incidence of Subjects With Treatment Emergent Adverse Events (TEAEs) | Safety as assessed by the incidence of treatment-emergent AEs (TEAEs). | First dose of study drug to 30-day post-dose follow up (Up to approximately 21 months) | |
Secondary | Median Duration of Response (DoR) | Duration of response is the interval from the date of initial CR or PR until the first date criteria for PD is met using RECIST v1.1 criteria, or initiation of other (or additional) antitumor therapy is first reported, or death due to any cause. | Date of Initial CR or PR to PD (Up to 21 Months) | |
Secondary | Progression-Free Survival (PFS) | PFS is defined as the time from the day of randomization to the first evidence of progression as defined by RECIST (RECIST v1.1) criteria or death from any cause. | Randomization to PD or Date of Death (Up to 21 Months) | |
Secondary | Plasma levels of CBX-12 (AUC0-24hr) | Assessment of pharmacokinetic (PK) variable AUC0-24hr | At 1st dose of study drug (pre-dose, end of infusion (EOI), 1, 2, and 4 hours post EOI), and 10-14 days post 1st dose | |
Secondary | Plasma levels of CBX-12 (Cmax) | Assessment of pharmacokinetic (PK) variable Cmax | At 1st dose of study drug (pre-dose, end of infusion (EOI), 1, 2, and 4 hours post EOI), and 10-14 days post 1st dose | |
Secondary | Plasma levels of CBX-12 (Tmax) | Assessment of pharmacokinetic (PK) variable Tmax | At 1st dose of study drug (pre-dose, end of infusion (EOI), 1, 2, and 4 hours post EOI), and 10-14 days post 1st dose | |
Secondary | Plasma levels of CBX-12 (T1/2) | Assessment of pharmacokinetic (PK) variable T1/2 | At 1st dose of study drug (pre-dose, end of infusion (EOI), 1, 2, and 4 hours post EOI), and 10-14 days post 1st dose | |
Secondary | Plasma levels of Exatecan (AUC0-24hr) | Assessment of pharmacokinetic (PK) variable AUC0-24hr | At 1st dose of study drug (pre-dose, end of infusion (EOI), 1 hour post EOI, 2 hours post EOI, 4 hours post EOI), and 10-14 days post 1st dose | |
Secondary | Plasma levels of Exatecan (Cmax) | Assessment of pharmacokinetic (PK) variable Cmax | At 1st dose of study drug (pre-dose, end of infusion (EOI), 1 hour post EOI, 2 hours post EOI, 4 hours post EOI), and 10-14 days post 1st dose | |
Secondary | Plasma levels of Exatecan (Tmax) | Assessment of pharmacokinetic (PK) variable Tmax | At 1st dose of study drug (pre-dose, end of infusion (EOI), 1 hour post EOI, 2 hours post EOI, 4 hours post EOI), and 10-14 days post 1st dose | |
Secondary | Plasma levels of Exatecan (T1/2) | Assessment of pharmacokinetic (PK) variable T1/2 | At 1st dose of study drug (pre-dose, end of infusion (EOI), 1 hour post EOI, 2 hours post EOI, 4 hours post EOI), and 10-14 days post 1st dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05494580 -
Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT05756907 -
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT04787289 -
A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer
|
Phase 2 | |
Completed |
NCT04504916 -
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)
|
Phase 2 | |
Recruiting |
NCT06090266 -
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05979298 -
Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT04376073 -
Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06321484 -
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT05271318 -
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer.
|
Phase 1 | |
Terminated |
NCT02575807 -
Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06242470 -
A Study of MGC026 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05310344 -
Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer
|
Phase 2 | |
Withdrawn |
NCT05736952 -
Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04374630 -
Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian
|
Phase 2 | |
Recruiting |
NCT05551507 -
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03949283 -
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
|
Phase 3 | |
Recruiting |
NCT05870748 -
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
|
Phase 2/Phase 3 | |
Recruiting |
NCT05198804 -
A Study of ZN-c3 and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT04718376 -
A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Relapsed Ovarian Cancer
|
Phase 1 | |
Recruiting |
NCT05081609 -
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or Chemotherapy or TransCon TLR7/8 Agonist in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
|
Phase 1/Phase 2 |